Jon Ellis
Directeur/Membre du Conseil chez Orchard Therapeutics (Europe) Ltd.
Postes actifs de Jon Ellis
Sociétés | Poste | Début | Fin |
---|---|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 02/08/2018 | - |
Historique de carrière de Jon Ellis
Anciens postes connus de Jon Ellis
Sociétés | Poste | Début | Fin |
---|---|---|---|
GSK PLC | Directeur Technique/Scientifique/R&D | 01/01/2001 | 01/08/2022 |
ORCHARD THERAPEUTICS PLC | Directeur/Membre du Conseil | 01/08/2018 | 16/06/2021 |
Independent Dir/Board Member | 01/08/2018 | 16/06/2021 |
Formation de Jon Ellis
University of Cambridge | Doctorate Degree |
Henley Management College | Masters Business Admin |
Magdalene College | Graduate Degree |
Statistiques
Internationale
Royaume-Uni | 7 |
Opérationnelle
Director/Board Member | 2 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectorielle
Consumer Services | 4 |
Health Technology | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
GSK PLC | Health Technology |
Entreprise privées | 2 |
---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |